Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pirenzepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.96 |
| ▸ | USP2 | O75604 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.96 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirenzepine SCHEMBL15300969 | 0.99 | LMNA (0.98) | LMNAGMNNAPEX1CHRM2CHRM1 | |
| Pirenzepine SCHEMBL41704 | 0.99 | LMNA (1.00) | LMNAGMNNAPEX1CHRM2CHRM1 | |
| Pirenzepine SCHEMBL30548470 | 0.99 | LMNA (1.00) | LMNAGMNNAPEX1CHRM2CHRM1 | |
| Pirenzepine SCHEMBL1462692 | 0.99 | LMNA (1.00) | LMNAGMNNAPEX1CHRM2CHRM1 | |
| Pirenzepine SCHEMBL11415337 | 0.98 | LMNA (0.98) | LMNAGMNNAPEX1CHRM2CHRM1 | |
| Pirenzepine SCHEMBL7985618 | 0.98 | LMNA (0.98) | LMNAGMNNAPEX1CHRM2CHRM1 | |
| Pirenzepine SCHEMBL30553045 | 0.98 | LMNA (1.00) | LMNAGMNNAPEX1CHRM2CHRM1 | |
| Pirenzepine SCHEMBL29793172 | 0.98 | LMNA (1.00) | LMNAGMNNAPEX1CHRM2CHRM1 | |
| Pirenzepine SCHEMBL41705 | 0.98 | LMNA (1.00) | LMNAGMNNAPEX1CHRM2CHRM1 | |
| Pirenzepine SCHEMBL9254860 | 0.98 | LMNA (1.00) | LMNAGMNNAPEX1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | claimed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | claimed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| JP-2023095805-A | PHARMACEUTICAL COMPOSITION, AND METHOD FOR STABILIZING PIRENZEPINE HYDROCHLORIDE HYDRATE AND SODIUM AZULENE SULFONATE HYDRATE | ライオン株式会社 | 2023-07-06 | — | — | JP | disclosed |
| JP-2022102122-A | PHARMACEUTICAL COMPOSITION, AND METHOD FOR STABILIZING PIRENZEPINE HYDROCHLORIDE HYDRATE | ライオン株式会社 | 2022-07-07 | — | — | JP | disclosed |
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | disclosed |
| EP-2465539-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2554184-B1 | PREVENTIVE AND/OR REMEDY FOR HAND AND FOOT SYNDROME | ONO PHARMACEUTICAL CO (JP) | 2016-10-26 | — | — | EP | disclosed |
| EP-2465540-B1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEM IND CO LTD (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-20130045956-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT OF HAND-FOOT SYNDROME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-02-21 | — | — | US | disclosed |
| EP-2554184-A1 | PREVENTIVE AND/OR REMEDY FOR HAND AND FOOT SYNDROME | ONO Pharmaceutical Co., Ltd. (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20120165413-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120156261-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-2465540-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465539-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-1397132-A4 | PIRENZEPINE OPHTHALMIC GEL | VALLEY FORGE PHARMACEUTICALS I (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1397132-A1 | PIRENZEPINE OPHTHALMIC GEL | Valley Forge Pharmaceuticals (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096418-A1 | PIRENZEPINE OPHTHALMIC GEL | VALLEY FORGE PHARMACEUTICALS (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | CHRM3, ACHE, CHRNB1 | CHRM1 8/4885LMNA 3777/4885GMNN 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.